BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cohen S, Tuckwell K, Katsumoto TR, Zhao R, Galanter J, Lee C, Rae J, Toth B, Ramamoorthi N, Hackney JA, Berman A, Damjanov N, Fedkov D, Jeka S, Chinn LW, Townsend MJ, Morimoto AM, Genovese MC. Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study). Arthritis Rheumatol 2020. [PMID: 32270926 DOI: 10.1002/art.41275] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 16.7] [Reference Citation Analysis]
Number Citing Articles
1 Vandeveer GH, Arduini RM, Baker DP, Barry K, Bohnert T, Bowden-Verhoek JK, Conlon P, Cullen PF, Guan B, Jenkins TJ, Liao SY, Lin L, Liu YT, Marcotte D, Mertsching E, Metrick CM, Negrou E, Powell N, Scott D, Silvian LF, Hopkins BT. Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse model. Bioorg Med Chem Lett 2023;80:129108. [PMID: 36538993 DOI: 10.1016/j.bmcl.2022.129108] [Reference Citation Analysis]
2 Merino-Vico A, Frazzei G, van Hamburg JP, Tas SW. Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches. Eur J Immunol 2023;53:e2149675. [PMID: 36314264 DOI: 10.1002/eji.202149675] [Reference Citation Analysis]
3 Smith CW, Harbi MH, Garcia-Quintanilla L, Rookes K, Brown H, Poulter NS, Watson SP, Nicolson PLR, Thomas MR. The Btk inhibitor AB-95-LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and platelet procoagulant activity. J Thromb Haemost 2022;20:2939-52. [PMID: 36239466 DOI: 10.1111/jth.15899] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Xiao M, Zhu M, Wu S, Ma L, Qi L, Ha S, Xiong S, Chen M, Chen D, Luo G, Xiang H. Novel 6-amino-1,3,5-triazine derivatives as potent BTK inhibitors: structure-activity relationship (SAR) analysis and preliminary mechanism investigation. Bioorganic Chemistry 2022. [DOI: 10.1016/j.bioorg.2022.106263] [Reference Citation Analysis]
5 Corneth OBJ, Neys SFH, Hendriks RW. Aberrant B Cell Signaling in Autoimmune Diseases. Cells 2022;11:3391. [DOI: 10.3390/cells11213391] [Reference Citation Analysis]
6 Fleischmann R, Friedman A, Drescher E, Singhal A, Cortes-maisonet G, Doan T, Lu W, Wang Z, Nader A, Housley W, Cohen S, Taylor PC, Blanco R. Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial. The Lancet Rheumatology 2022;4:e395-e406. [DOI: 10.1016/s2665-9913(22)00092-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Robak E, Robak T. Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives. J Clin Med 2022;11:2807. [PMID: 35628931 DOI: 10.3390/jcm11102807] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
8 Roškar S, Hafner-bratkovič I. The Role of Inflammasomes in Osteoarthritis and Secondary Joint Degeneration Diseases. Life 2022;12:731. [DOI: 10.3390/life12050731] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Christensen BW, Zaha VG, Awan FT. Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. Expert Rev Hematol 2022;:1-11. [PMID: 35437106 DOI: 10.1080/17474086.2022.2067526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Owens TD, Brameld KA, Verner EJ, Ton T, Li X, Zhu J, Masjedizadeh MR, Bradshaw JM, Hill RJ, Tam D, Bisconte A, Kim EO, Francesco M, Xing Y, Shu J, Karr D, LaStant J, Finkle D, Loewenstein N, Haberstock-Debic H, Taylor MJ, Nunn P, Langrish CL, Goldstein DM. Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib). J Med Chem 2022. [PMID: 35302767 DOI: 10.1021/acs.jmedchem.1c01170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
11 Liang J, Wu W, Wang X, Wu W, Chen S, Jiang M, M.a B. Analysis of Sepsis Markers and Pathogenesis Based on Gene Differential Expression and Protein Interaction Network. Journal of Healthcare Engineering 2022;2022:1-7. [DOI: 10.1155/2022/6878495] [Reference Citation Analysis]
12 Robak T, Witkowska M, Smolewski P. The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions. Cancers 2022;14:771. [DOI: 10.3390/cancers14030771] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
13 Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 2022. [PMID: 34987201 DOI: 10.1038/s41584-021-00726-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 27.0] [Reference Citation Analysis]
14 杨 婉. Research Progress of BTK Inhibitors in the Treatment of Inflammatory and Autoimmune Diseases. HJMCe 2022;10:70-83. [DOI: 10.12677/hjmce.2022.101008] [Reference Citation Analysis]
15 Schneider R, Oh J. Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis. Curr Neurol Neurosci Rep 2022;22:721-34. [PMID: 36301434 DOI: 10.1007/s11910-022-01229-z] [Reference Citation Analysis]
16 Föll D, Kallinich T. Weiterentwicklung in der Therapie rheumatischer Erkrankungen bei Kindern und Jugendlichen. Pädiatrische Rheumatologie 2022. [DOI: 10.1007/978-3-662-60410-6_24] [Reference Citation Analysis]
17 Tanaka Y. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology (Oxford) 2021;60:vi12-20. [PMID: 34951925 DOI: 10.1093/rheumatology/keab609] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
18 Dang VD, Stefanski AL, Lino AC, Dörner T. B- and Plasma Cell Subsets in Autoimmune Diseases: Translational Perspectives. J Invest Dermatol 2021:S0022-202X(21)02470-2. [PMID: 34955289 DOI: 10.1016/j.jid.2021.05.038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Ringheim GE, Wampole M, Oberoi K. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures. Front Immunol 2021;12:662223. [PMID: 34803999 DOI: 10.3389/fimmu.2021.662223] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
20 Hopkins BT, Bame E, Bajrami B, Black C, Bohnert T, Boiselle C, Burdette D, Burns JC, Delva L, Donaldson D, Grater R, Gu C, Hoemberger M, Johnson J, Kapadnis S, King K, Lulla M, Ma B, Marx I, Magee T, Meissner R, Metrick CM, Mingueneau M, Murugan P, Otipoby KL, Polack E, Poreci U, Prince R, Roach AM, Rowbottom C, Santoro JC, Schroeder P, Tang H, Tien E, Zhang F, Lyssikatos J. Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. J Med Chem 2021. [PMID: 34734694 DOI: 10.1021/acs.jmedchem.1c00926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
21 Takanashi S, Kaneko Y, Takeuchi T. Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice. Rheumatology (Oxford) 2021;60:5247-56. [PMID: 33682890 DOI: 10.1093/rheumatology/keab209] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
22 Kufukihara K. Anti‐B cell therapies in multiple sclerosis. Clinical & Exp Neuroim 2021;12:228-237. [DOI: 10.1111/cen3.12679] [Reference Citation Analysis]
23 Vadasz Z, Toubi E. New Biological Treatment Options in CSU. Urticaria - Diagnosis and Management 2021. [DOI: 10.5772/intechopen.97647] [Reference Citation Analysis]
24 Wu F, Gao J, Kang J, Wang X, Niu Q, Liu J, Zhang L. B Cells in Rheumatoid Arthritis:Pathogenic Mechanisms and Treatment Prospects. Front Immunol 2021;12:750753. [PMID: 34650569 DOI: 10.3389/fimmu.2021.750753] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
25 Meng A, Humeniuk R, Jürgensmeier JM, Hsueh CH, Matzkies F, Grant E, Truong H, Billin AN, Yu H, Feng J, Kwan E, Tarnowski T, Nelson CH. Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA. Clin Pharmacol Ther 2021. [PMID: 34623640 DOI: 10.1002/cpt.2439] [Reference Citation Analysis]
26 Byun JY, Koh YT, Jang SY, Witcher JW, Chan JR, Pustilnik A, Daniels MJ, Kim YH, Suh KH, Linnik MD, Lee YM. Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection. Sci Rep 2021;11:18671. [PMID: 34548595 DOI: 10.1038/s41598-021-98255-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Weber MS, Nicholas JA, Yeaman MR. Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic. Neurol Neuroimmunol Neuroinflamm 2021;8:e1067. [PMID: 34497100 DOI: 10.1212/NXI.0000000000001067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
28 Arneson LC, Carroll KJ, Ruderman EM. Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis. Immunotargets Ther 2021;10:333-42. [PMID: 34485183 DOI: 10.2147/ITT.S288550] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
29 Zhang D, Gong H, Meng F. Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases. Molecules 2021;26:4907. [PMID: 34443496 DOI: 10.3390/molecules26164907] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
30 Giménez-Arnau AM, Salman A. Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress. Drugs 2020;80:1617-34. [PMID: 32857360 DOI: 10.1007/s40265-020-01387-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
31 Roszkowski L, Ciechomska M. Tuning Monocytes and Macrophages for Personalized Therapy and Diagnostic Challenge in Rheumatoid Arthritis. Cells 2021;10:1860. [PMID: 34440629 DOI: 10.3390/cells10081860] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
32 Weeks S, Harris R, Karimi M. Targeting ITK signaling for T cell-mediated diseases. iScience 2021;24:102842. [PMID: 34368657 DOI: 10.1016/j.isci.2021.102842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Neys SFH, Hendriks RW, Corneth OBJ. Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies. Front Cell Dev Biol 2021;9:668131. [PMID: 34150760 DOI: 10.3389/fcell.2021.668131] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
34 Isenberg D, Furie R, Jones NS, Guibord P, Galanter J, Lee C, McGregor A, Toth B, Rae J, Hwang O, Desai R, Lokku A, Ramamoorthi N, Hackney JA, Miranda P, de Souza VA, Jaller-Raad JJ, Maura Fernandes A, Garcia Salinas R, Chinn LW, Townsend MJ, Morimoto AM, Tuckwell K. Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 2021. [PMID: 34042314 DOI: 10.1002/art.41811] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
35 Tichenor MS, Wiener JJM, Rao NL, Pooley Deckhut C, Barbay JK, Kreutter KD, Bacani GM, Wei J, Chang L, Murrey HE, Wang W, Ahn K, Huber M, Rex E, Coe KJ, Wu J, Seierstad M, Bembenek SD, Leonard KA, Lebsack AD, Venable JD, Edwards JP. Discovery of a Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase with Oral Anti-Inflammatory Activity. ACS Med Chem Lett 2021;12:782-90. [PMID: 34055226 DOI: 10.1021/acsmedchemlett.1c00044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
36 Kaul M, End P, Cabanski M, Schuhler C, Jakab A, Kistowska M, Kinhikar A, Maiolica A, Sinn A, Fuhr R, Cenni B. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clin Transl Sci 2021. [PMID: 33834628 DOI: 10.1111/cts.13005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
37 Estupiñán HY, Berglöf A, Zain R, Smith CIE. Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. Front Cell Dev Biol 2021;9:630942. [PMID: 33777941 DOI: 10.3389/fcell.2021.630942] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 23.5] [Reference Citation Analysis]
38 Liu J, Ting JP, Al-Azzam S, Ding Y, Afshar S. Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases. Int J Mol Sci 2021;22:2805. [PMID: 33802091 DOI: 10.3390/ijms22062805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 von Hundelshausen P, Siess W. Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. Cancers (Basel) 2021;13:1103. [PMID: 33806595 DOI: 10.3390/cancers13051103] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
40 Föll D, Kallinich T. Weiterentwicklung in der Therapie rheumatischer Erkrankungen bei Kindern und Jugendlichen. Pädiatrische Rheumatologie 2021. [DOI: 10.1007/978-3-662-60411-3_24-1] [Reference Citation Analysis]
41 Bilal M, Qindeel M, Nunes LV, Duarte MTS, Ferreira LFR, Soriano RN, Iqbal HMN. Marine-Derived Biologically Active Compounds for the Potential Treatment of Rheumatoid Arthritis. Mar Drugs 2020;19:10. [PMID: 33383638 DOI: 10.3390/md19010010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
42 Schwaid AG, Spencer KB. Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space. J Med Chem 2021;64:101-22. [PMID: 33351619 DOI: 10.1021/acs.jmedchem.0c01307] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 9.7] [Reference Citation Analysis]
43 Harbi MH, Smith CW, Nicolson PLR, Watson SP, Thomas MR. Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases. Platelets 2021;32:29-41. [PMID: 33307909 DOI: 10.1080/09537104.2020.1849600] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
44 Srivastava AS, Ko S, Watterson SH, Pattoli MA, Skala S, Cheng L, Obermeier MT, Vickery R, Discenza LN, D'Arienzo CJ, Gillooly KM, Taylor TL, Pulicicchio C, McIntyre KW, Yip S, Li P, Sun D, Wu DR, Dai J, Wang C, Zhang Y, Wang B, Pawluczyk J, Kempson J, Zhao R, Hou X, Rampulla R, Mathur A, Galella MA, Salter-Cid L, Barrish JC, Carter PH, Fura A, Burke JR, Tino JA. Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK. ACS Med Chem Lett 2020;11:2195-203. [PMID: 33214829 DOI: 10.1021/acsmedchemlett.0c00335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
45 Siess W, Hundelshausen PV, Lorenz R. Selective inhibition of thromboinflammation in COVID-19 by Btk inhibitors. Platelets 2020;31:989-92. [PMID: 32892684 DOI: 10.1080/09537104.2020.1809647] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
46 Nicolson PL, Welsh JD, Chauhan A, Thomas MR, Kahn ML, Watson SP. A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors. Platelets 2020;31:685-90. [PMID: 32552307 DOI: 10.1080/09537104.2020.1775189] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 9.7] [Reference Citation Analysis]